^
Association details:
| Biomarker: | MLL3 mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P60.13 - Association of KMT2C/D Mutations with Tumor Mutation Burden and Response to Immune Checkpoint Inhibitors in NSCLC
Published date:
01/12/2021
Excerpt:
...patients in the MT group had a significantly longer median PFS (5.4 vs 3.6 months, HR: 0.69 [95%CI: 0.51-0.92], P = 0.024) with PD-(L)1 therapy or combination PD-1 and CTLA-4….KMT2C/D mutations are frequent in NSCLC and are associated with higher TMB and improved clinical outcomes in NSCLC patients treated with ICIs.
